- Approval Id
- 930000f7370ccfa1
- Drug Approval Emc Name
- Gavreto 100 mg hard capsules
- Drug Name
- Gavreto 100 mg hard capsules
- Company Address
- Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW
- Company Website
- http://www.roche.co.uk
- Company Telephone
- +44 (0)1707 366 000
- Company Medical Info Direct Line
- +44 (0)800 328 1629
- Company Medical Info Email
- medinfo.uk@roche.com
- Company Customer Care Direct Line
- +44 (0)800 731 5711
- Company Medical Info Fax
- +44 (0)1707 384555
- Atc Code
- L01EX23
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Roche Products Limited
6 Falcon Way, Shire Park
Welwyn Garden City
AL7 1TW
United Kingdom
- Authorisation Number
- PLGB 00031/0929
- Authorisation Date
- 13 December 2023
- Instruction Authorisation Holder
- Roche Products Limited
6 Falcon Way, Shire Park
Welwyn Garden City
AL7 1TW
United Kingdom
- Instruction Authorisation Number
- PLGB 00031/0929
- Instruction Authorisation Date
- 13 December 2023
- Instruction Composition
- Each hard capsule contains 100 mg of pralsetinib.
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Hard capsule.
Light blue, opaque hard capsule, size 0 (22 mm long x 7 mm wide) with “BLU-667” printed on the capsule shell body and “100 mg” on the capsule shell cap in white ink.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.4.2 Posology and method of administration
Therapy should be initiated by a physician experienced in the administration of anticancer medicinal products.
Patient selection for treatment of RET fusion-positive advanced NSCLC should be based on a validated test method.
\*\*Posology\*\*
The recommended dose is 400 mg pralsetinib once daily on an empty stomach (see method of administration). Treatment should be continued until disease progression or unacceptable toxicity.
If vomiting occurs after taking a dose of pralsetinib, the patient should not take an additional dose but continue with the next scheduled dose.
\*Missed doses\*
If a dose of pralsetinib is missed, the patient should make up for the missed dose as soon as possible on the same day. The regular daily dose schedule for pralsetinib should be resumed the next day.
\*Dose modifications for adverse reactions\*
Interruption of treatment with or without dose reduction may be considered to manage adverse reactions based on severity and clinical presentation.
Patients may have their dose reduced by 100 mg decrements to a minimum dose of 100 mg once daily. Gavreto should be permanently discontinued in patients who are unable to tolerate 100 mg orally once daily.
Recommended dose modifications for adverse reactions are indicated in Table 1.
\*\*Table 1. Recommended dose modifications for Gavreto for adverse reactions\*\*
| | | |
| --- | --- | --- |
| \*\*Adverse reaction\*\* | \*\*Severitya\*\* | \*\*Dose modification\*\* |
| \*\*Pneumonitis/Interstitial lung disease (ILD)\*\* (see section 4.4) | Grade 1 or 2 | Interrupt treatment with Gavreto until resolution. Resume at a reduced dose. Permanently discontinue Gavreto for recurrent pneumonitis/ILD. |
| Grade 3 or 4 | Permanently discontinue for pneumonitis/ILD. |
| \*\*Hypertension\*\* | Grade 3 | Interrupt treatment with Gavreto for Grade 3 hypertension that persists despite optimal antihypertensive therapy. Resume at a reduced dose when hypertension is controlled. |
| Grade 4 | Permanently discontinue Gavreto. |
| \*\*Transaminase elevations\*\* | Grade 3 or 4 | Interrupt treatment with Gavreto and monitor aspartate aminotransferase (AST) and alanine aminotransferase (ALT) once weekly until resolution to Grade 1 or baseline. Resume at a reduced dose. If the transaminase elevation recurs at Grade 3 or higher, permanently discontinue treatment with Gavreto. |
| \*\*Haemorrhagic events\*\* | Grade 3 or 4 | Interrupt treatment with Gavreto until resolution to Grade 1. Resume at a reduced dose. Permanently discontinue Gavreto for life-threatening or recurrent severe haemorrhagic events. |
| \*\*QT prolongation\*\* | Grade 3 | Interrupt treatment with Gavreto for QTc intervals >500 ms until QTc interval returns to <470 ms. Resume at the same dose if risk factors that cause QT prolongation are identified and corrected. Resume treatment at a reduced dose if other risk factors that cause QT prolongation are not identified. |
| Grade 4 | Permanently discontinue Gavreto if the patient has life-threatening arrhythmia. |
| \*\*Other clinically significant adverse reactions\*\* (see section 4.8) | Grade 3 or 4 | Interrupt treatment with Gavreto until improvement to ≤Grade 2. Resume at a reduced dose. Permanently discontinue for recurrent Grade 4 adverse reactions. |
| a Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 | | |
\*Dose modification for use with strong cytochrome P-450 (CYP)3A4 inhibitors or combined P-glycoprotein (P-gp) and strong CYP3A4 inhibitors\*
Concomitant use of pralsetinib with known strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors should be avoided (see section 4.4 and section 4.5). If co-administration with a strong CYP3A4 inhibitor or combined P-gp and strong CYP3A4 inhibitor cannot be avoided, the current dose of pralsetinib should be reduced as recommended in Table 2. After the strong CYP3A4 inhibitor or combined P-gp and strong CYP3A4 inhibitor have been discontinued for 3 to 5 elimination half-lives, the pralsetinib dose that was taken prior to the use of the inhibitor should be resumed.
\*\*Table 2. Recommended dose modifications for Gavreto for co-administration with strong CYP3A4 inhibitors or combined P\*\*-\*\*gp and strong CYP3A4 inhibitors\*\*
| | |
| --- | --- |
| \*\*Current Gavreto dose\*\* | \*\*Recommended Gavreto dose\*\* |
| 400 mg orally once daily | 200 mg orally once daily |
| 300 mg orally once daily | 200 mg orally once daily |
| 200 mg orally once daily | 100 mg orally once daily |
\*Dose modification for use with strong CYP3A4 inducers\*
Concomitant use of pralsetinib with strong CYP3A4 inducers should be avoided (see section 4.4 and section 4.5).
If concomitant use with a strong CYP3A4 inducer cannot be avoided, the dose of pralsetinib should be increased to double the current pralsetinib dose starting on Day 7 of co-administration of pralsetinib with the strong CYP3A4 inducer. After the strong CYP3A4 inducer has been discontinued for at least 14 days, the pralsetinib dose that was taken prior to the use of the inducer should be resumed.
\*\*Special populations\*\*
\*Renal impairment\*
No dose adjustment is recommended for patients with mild or moderate renal impairment (creatinine clearance [CLCR] 30 to 89 mL/min estimated by Cockcroft-Gault). Pralsetinib has not been studied in patients with severe renal impairment (CLCR 15 to 29 mL/min) or end-stage renal disease (CLCR <15 mL/min). Since pralsetinib elimination via the kidney is negligible, no dose adjustment is required in patients with severe renal impairment or end-stage renal disease (see section 5.2).
\*Hepatic impairment\*
No dose adjustment is recommended for patients with mild (total bilirubin ≤ upper limit of normal [ULN] and aspartate aminotransferase [AST] > ULN or total bilirubin > 1 to 1.5 times ULN and any AST), moderate (total bilirubin > 1.5 to 3 times ULN and any AST) or severe hepatic impairment (total bilirubin > 3 times ULN and any AST) (see section 5.2).
\*Elderly\*
No dose adjustment is recommended for patients aged 65 years and above (see section 5.1).
\*Paediatric population\*
The safety and efficacy of pralsetinib in paediatric patients below 18 years of age with RET fusion-positive advanced NSCLC have not been established. No data are available.
\*\*Method of administration\*\*
Gavreto is for oral use. Patients should swallow the hard capsules whole with a glass of water, on an empty stomach. They should not eat for at least two hours before and at least one hour after taking pralsetinib (see section 5.2).4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.4.4 Special warnings and precautions for use
\*\*Pneumonitis/ILD\*\*
Severe, life-threatening or fatal cases of pneumonitis/ILD have been reported in patients who received pralsetinib in clinical trials (see section 4.8). Patients who present with clinically symptomatic pneumonitis or ILD were excluded from clinical trials.
Patients should be advised to contact their healthcare provider immediately to report new or worsening respiratory symptoms.
Patients who present with acute or worsening of respiratory symptoms indicative of pneumonitis/ILD (e.g., dyspnoea, cough, and fever) should be investigated to exclude other potential causes. If pneumonitis/ILD is considered to be related to pralsetinib, the dose of Gavreto should be interrupted, reduced or permanently discontinued based on severity of confirmed pneumonitis/ILD (see section 4.2).
\*\*Hypertension\*\*
Hypertension was observed in pralsetinib-treated patients in clinical trials (see section 4.8). Treatment-related hypertension was most commonly managed with anti-hypertensive medicinal products.
Treatment with Gavreto should not be initiated in patients with uncontrolled hypertension. Pre-existing hypertension should be adequately controlled before starting Gavreto treatment. Monitoring of blood pressure is recommended after 1 week, at least monthly thereafter and as clinically indicated. Anti-hypertensive therapy should be initiated or adjusted as appropriate. The dose should be interrupted, reduced, or permanently discontinued based on the severity of hypertension observed during treatment with Gavreto (see section 4.2).
\*\*Transaminase elevations\*\*
Severe cases of transaminase elevations have been reported in patients who received pralsetinib in clinical trials (see section 4.8).
ALT and AST should be monitored prior to initiating Gavreto, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Treatment with Gavreto should be interrupted, reduced or permanently discontinued based on severity of the transaminase elevation observed during treatment with Gavreto (see section 4.2).
\*\*Haemorrhagic events\*\*
Severe, including fatal, haemorrhagic events can occur with Gavreto. In patients with life-threatening or recurrent severe haemorrhage, Gavreto should be permanently discontinued (see section 4.2).
\*\*QT prolongation\*\*
Prolongation of the QT interval has been observed in patients who received Gavreto in clinical trials (see section 4.8). Therefore, before starting Gavreto treatment, patients should have a QTc interval ≤470 ms and serum electrolytes within normal range. Hypokalaemia, hypomagnesaemia, and hypocalcaemia should be corrected both prior and during Gavreto treatment. Electrocardiograms (ECGs) and serum electrolytes should be monitored at the end of the first week and of the first month of Gavreto treatment, then periodically, as clinically indicated, depending also on presence of other risk factors (e.g. intercurrent diarrhoea, vomiting, nausea, concomitant medications).
Pralsetinib should be used with caution in patients with medical history of cardiac arrhythmias or QT interval prolongation, as well as in patients on strong CYP 3A4 inhibitors or on medicinal products known to be associated with QT/QTc prolongation.
Gavreto may require interruption, dose modification, or discontinuation (see section 4.2).
\*\*Tuberculosis\*\*
Tuberculosis, mostly extrapulmonary, has been reported in patients receiving Gavreto. Before starting treatment, patients should be evaluated for active and inactive (“latent”) tuberculosis, as per local recommendations. In patients with active or latent tuberculosis, standard antimycobacterial therapy should be initiated before treatment with Gavreto is started.
\*\*Drug interactions\*\*
Co-administration of Gavreto with strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors should be avoided because they may increase the plasma concentration of pralsetinib (see sections 4.2 and 4.5).
Co-administration of Gavreto with strong CYP3A4 inducers should be avoided because they may decrease the plasma concentration of pralsetinib (see section 4.2 and section 4.5).
\*\*Fertility and pregnancy\*\*
During treatment with Gavreto and for at least 1 week after the final dose, male patients with female partners of childbearing potential must use effective contraception, including a barrier method (see section 4.6).
Women of childbearing potential should be advised to avoid becoming pregnant while receiving Gavreto. A highly effective non-hormonal method of contraception is required for female patients during treatment with pralsetinib, because pralsetinib can render hormonal contraceptives ineffective. If a hormonal method of contraception is unavoidable, then a condom must be used in combination with the hormonal method. Effective contraception must be continued for at least 2 weeks after the final dose (see section 4.6)\*.\*
\*\*Sodium content\*\*
This medicinal product contains less than 1 mmol sodium (23 mg) per hard capsule, that is to say essentially “sodium-free”.4.5 Interaction with other medicinal products and other forms of interaction
\*\*Pharmacokinetic interactions\*\*
\*In vitro\* data indicate that pralsetinib is primarily metabolised by CYP3A4 and transported by P-gp. Therefore, inducers and inhibitors of CYP3A4 and P-gp may alter the plasma concentrations of pralsetinib.
\*\*Active substances that may have an effect on pralsetinib\*\*
\*Strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors\*
Co-administration of pralsetinib with strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors can increase pralsetinib plasma concentrations, which may increase the incidence and severity of adverse reactions of pralsetinib. Co-administration of 200 mg pralsetinib once daily with itraconazole 200 mg once daily (a strong CYP3A4 and P-gp inhibitor) increased pralsetinib Cmax by 84% and AUC0-∞ by 251%, compared to pralsetinib administered alone.
Therefore, co-administration of pralsetinib with strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors (including, but not limited to, ritonavir, saquinavir, telithromycin, ketoconazole, itraconazole, voriconazole, posaconazole nefazodone, grapefruit or Seville oranges) should be avoided (see section 4.4). If co-administration with strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors cannot be avoided, reduce the current dose of pralsetinib (section 4.2).
\*Strong CYP3A4 inducers\*
Co-administration of pralsetinib with strong CYP3A4 inducers can decrease pralsetinib plasma concentrations, which may decrease the efficacy of pralsetinib. Co-administration of 400 mg pralsetinib as a single dose with rifampin 600 mg once daily (a strong CYP3A4 inducer) decreased pralsetinib Cmax by 30% and AUC0-∞ by 68%. Based on a population PK analysis, CYP3A4 weak inducers decreased pralsetinib exposures, but were not clinically significant in patients with NSCLC.
Therefore, co-administration of pralsetinib with strong CYP3A4 inducers (including, but not limited to, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin and St. John's Wort [\*Hypericum perforatum\*]) should be avoided (see section 4.4). If co-administration cannot be avoided, increase the pralsetinib dose (see section 4.2).
\*Sensitive substrates of CYP3A4, CYP2C8, CYP2C9, P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1 and MATE2-K with narrow therapeutic index\*
Co-administration of pralsetinib can alter the exposure of sensitive substrates of CYP enzymes (CYP3A4, CYP2C9 and CYP2C8) and transporters (P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1 and MATE2-K)\*.\* Substrate drugs of these CYP enzymes and transporters with narrow therapeutic index (including, but not limited to cyclosporine, paclitaxel and warfarin) should be avoided.4.6 Fertility, pregnancy and lactation
\*\*Women of childbearing potential/Contraception in females and males\*\*
Women of childbearing potential should be informed that pralsetinib may cause foetal harm (see section 5.3).
The pregnancy status of women of childbearing potential should be verified prior to initiating Gavreto treatment.
Women of childbearing potential have to use highly effective non-hormonal contraception during treatment and for at least 2 weeks following the last dose of Gavreto (see section 4.4).
Males with female partners of childbearing potential must use effective contraception during, including a barrier method, treatment with Gavreto and for at least 1 week following the last dose of Gavreto.
Patients should be advised to contact their healthcare provider immediately if they become pregnant, or if pregnancy is suspected, while taking Gavreto.
\*\*Pregnancy\*\*
There are no data from the use of pralsetinib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).
Based on its mechanism of action and findings in animals, pralsetinib may cause foetal harm when administered to pregnant women.
Gavreto should not be used during pregnancy unless the clinical condition of the woman requires treatment with pralsetinib.
\*\*Breast-feeding\*\*
It is unknown whether pralsetinib or its metabolites are excreted in human milk.
A risk to the breast-fed child cannot be excluded.
Breast-feeding should be discontinued during treatment with Gavreto and for 1 week following the final dose.
\*\*Fertility\*\*
There is no clinical data on the effects of pralsetinib on fertility.
Based on non-clinical safety findings, fertility may be compromised during treatment with pralsetinib (see section 5.3). Men and women should seek advice on effective fertility preservation before treatment.4.7 Effects on ability to drive and use machines
Gavreto has minor influence on the ability to drive and use machines. Caution should be exercised when driving or operating machines as patients may experience fatigue while taking Gavreto (see section 4.8).4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
The most common adverse reactions were anaemia (53.0%), aspartate aminotransferase increased (49.1%), neutropenia (46.7%), musculoskeletal pain (44.4%), constipation (43.9%), fatigue (42.2%), alanine aminotransferase increased (37.0%), leukopenia (37.0%), and hypertension (35.0%).
The most common serious adverse reactions were pneumonia (15.6%), pneumonitis (5.7%) and anaemia (5.2%).
The most common severe adverse reactions were anaemia (22.4%), neutropenia (21.1%), hypertension (17.6%), pneumonia (15.4%), and lymphopenia (17.4%).
Based on the data from clinical trials, exposure-response relationships for any Grade 3 or 4 adverse reaction were observed at higher exposures, with a faster time to onset for adverse reactions with increasing pralsetinib exposure.
Dose reductions due to adverse reactions occurred in 46.7% of patients treated with Gavreto. The most common adverse reactions resulting in dose reductions were neutropenia (15.6%), anaemia (10.6%), lymphopenia (7.2%), pneumonitis (5.7%), blood creatine phosphokinase increased (5.2%), leukopenia (4.6%), hypertension (4.8%), and fatigue (4.1%).
Permanent discontinuation due to adverse reactions occurred in 10.6% of patients treated with Gavreto. The most common adverse reactions that led to permanent discontinuation of Gavreto were pneumonia and pneumonitis (2.6% and 2.2%, respectively).
\*\*Tabulated list of adverse reactions\*\*
The safety population includes a total of 540 patients, including 281 patients with advanced NCSLC, as well as patients with other solid tumours (including RET fusion thyroid cancer and RET mutation medullary thyroid cancer), who received pralsetinib at a starting dose of 400 mg, see section 5.1. No clinically relevant differences in the safety profile across indications have been observed.
Adverse reactions reported in patients treated with Gavreto in the ARROW trial are listed below (Table 3), according to the MedDRA System Organ Class and frequency.
Frequencies are defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), and not known (cannot be estimated from the available data).
Within each system organ class, adverse reactions are presented in order of decreasing frequency and severity.
| | | | |
| --- | --- | --- | --- |
| \*\*Table 3.\*\* \*\*Adverse reactions reported in all patients treated with 400 mg Gavreto in the ARROW trial (N=540)\*\* | | | |
| \*\*System organ class /\*\* Adverse reactions | \*\*Frequency category\*\* | \*\*All grades\*\* \*\*%\*\* | \*\*Grades 3-4\*\* \*\*%\*\* |
| \*\*Infections and infestations\*\* | | | |
| Pneumonia1 Urinary tract infection | Very common | 22.4 14.8 | 13.1 4.4 |
| \*\*Blood and lymphatic system disorders\*\* | | | |
| Anaemia2 Neutropenia3 Leukopenia4 Lymphopenia5 Thrombocytopenia6 | Very common | 53.0 46.7 37.0 26.9 19.6 | 22.421.1 8.9 17.4 4.8 |
| \*\*Metabolism and nutrition disorders\*\* | | | |
| Hypocalcaemia Hyperphosphataemia Hypoalbuminaemia Hypophosphataemia Hyponatraemia | Very common | 23.1 17.4 14.8 13.0 12.2 | 3.9 0.2 - 5.7 4.4 |
| \*\*Nervous system disorders\*\* | | | |
| Headache7 Taste disorder8 | Very common | 18.0 16.7 | 0.6 - |
| \*\*Vascular disorders\*\* | | | |
| Hypertension9 Haemorrhage10 | Very common | 35.0 20.6 | 17.6 3.9 |
| \*\*Respiratory, thoracic and mediastinal disorders\*\* | | | |
| Cough11 Dyspnoea Pneumonitis12 | Very common | 28.1 20.4 12.2 | 0.6 2.0 3.3 |
| \*\*Gastrointestinal disorders\*\* | | | |
| Constipation Diarrhoea Nausea Abdominal pain13 Dry mouth Vomiting | Very common | 43.9 33.1 19.6 17.8 16.5 14.8 | 0.6 3.1 0.2 1.5 - 1.1 |
| Stomatitis14 | Common | 6.9 | 1.3 |
| \*\*Hepatobiliary disorders\*\* | | | |
| Aspartate aminotransferase increased\\* Alanine aminotransferase increased\\* Hyperbilirubinaemia15 | Very common | 49.1 37.0 14.4 | 6.9 4.8 1.7 |
| \*\*Skin and subcutaneous tissue disorders\*\* | | | |
| Rash16 | Very common | 19.1 | - |
| \*\*Musculoskeletal and connective tissue disorders\*\* | | | |
| Musculoskeletal pain17 Blood creatine phosphokinase increased | Very common | 44.4 16.7 | 2.6 7.6 |
| \*\*General disorders and administration site conditions\*\* | | | |
| Fatigue18 Oedema19 Pyrexia | Very common | 42.2 31.5 27.8 | 4.1 0.2 1.5 |
| \*\*Cardiac disorders\*\* | | | |
| QT prolongation20 | Common | 5.2 | 0.4 |
| \*\*Renal and urinary disorders\*\* | | | |
| Blood creatinine increased | Very common | 25.4 | 0.6 |
| \*\*Investigations\*\* | | | |
| Blood alkaline phosphatase increased | Very common | 12.0 | 1.5 |
| 1 includes pneumonia, pneumocystis jirovecii pneumonia, pneumonia cytomegaloviral, atypical pneumonia, lung infection, pneumonia bacterial, pneumonia haemophilus, pneumonia influenzal, pneumonia streptococcal, pneumonia moraxella, pneumonia staphylococcal, pneumonia pseudomonal, atypical mycobacterial pneumonia, pneumonia legionella 2 includes anaemia, haematocrit decreased, red blood cell count decreased, haemoglobin decreased, aplastic anaemia 3 includes neutrophil count decreased, neutropenia 4 includes white blood cell count decreased, leukopenia 5 includes lymphopenia, lymphocyte count decreased 6 includes thrombocytopenia, platelet count decreased 7 includes headache, tension headache 8 includes ageusia, dysgeusia 9 includes hypertension, blood pressure increased 10 includes 39 preferred terms from the SMQ Haemorrhage (excl laboratory terms) narrow, with the exclusion of terms related to invasive drug administration, terms related to rupture, disseminated intravascular coagulopathy, terms related to traumatic haemorrhages, and haemorrhagic terms related to pregnancy, birth or neonatal 11 includes cough, productive cough 12 includes pneumonitis, interstitial lung disease 13 includes abdominal pain, abdominal pain upper 14 includes stomatitis, aphthous ulcer 15 includes blood bilirubin increased, hyperbilirubinaemia, bilirubin conjugated increased, blood bilirubin unconjugated increased 16 includes rash, rash maculo-papular, dermatitis acneiform, erythema, rash generalised, rash papular, rash pustular, rash macular, rash erythematous 17 includes musculoskeletal chest pain, myalgia, arthralgia, pain in extremity, neck pain, musculoskeletal pain, back pain, bone pain, spinal pain, musculoskeletal stiffness 18 includes asthenia, fatigue 19 includes oedema, swelling face, peripheral swelling, oedema peripheral, face oedema, periorbital oedema, eyelid oedema, generalised oedema, swelling, localised oedema 20 includes electrocardiogram QT prolonged, long QT syndrome \\* additionally, transaminases increased were reported in 3.7% (0.6% Grades 3-4) | | | |
\*\*Description of selected adverse reactions\*\*
\*\*\*Pneumonitis/ILD\*\*\*
Pneumonitis and ILD occurred in 12.2% of 540 patients with NSCLC or other solid tumours, enrolled in the ARROW Study who received Gavreto (see section 4.4). Among the patients who had pneumonitis/ILD, the median time to onset was 16.1 weeks.
Serious adverse reactions of pneumonitis/ILD were reported for 5.7% of patients, including Grade 3 events (2.8%), Grade 4 (0.6%) and one fatal (Grade 5) event (0.2%).
In clinical trials, the majority of the patients with Grade 1 or Grade 2 pneumonitis were able to continue treatment without recurrent pneumonitis/ILD following dose interruption and dose reduction. Dose interruption occurred in 8.9%, dose reduction in 5.7% and permanent dose discontinuation in 2.2% of patients due to ILD/pneumonitis. The median time to resolution was 4.3 weeks.
\*\*\*Hypertension\*\*\*
Hypertension (including blood pressure increased) occurred in 35.0% of 540 patients with NSCLC or other solid tumours, including Grade ≤2 events in 17.4% and Grade 3 in 17.6% of patients. No Grade 4 or Grade 5 events were reported. Among the patients who had hypertension, the median time to onset was 2.1 weeks.
Serious adverse reactions of hypertension were reported in 1.3% of all patients (all Grade 3 events).
Dose interruption occurred in 8.0% of patients, dose reduction in 4.8% and one patient (0.2%) required permanent dose discontinuation. The median time to resolution was 4.0 weeks.
\*\*\*Transaminase elevations\*\*\*
Increased AST occurred in 49.1% of 540 patients, including Grade 3 or 4 in 6.9% of patients. Increased ALT occurred in 37.0% of patients, including Grade 3 or 4 events in 4.8% of patients. The median time to first onset for increased AST was 2.1 weeks and increased ALT was 3.5 weeks.
Serious adverse reactions of increased AST and ALT were reported in 0.7% and 0.6% of patients, respectively.
Dose interruption due to increased AST or ALT occurred in 5.0% and 3.9% of patients, respectively and dose reduction in 2.0% and 1.5%, respectively. No patients required permanent dose discontinuation. The median time to resolution was 6.0 and 5.1 weeks for increased AST and ALT, respectively.
\*\*\*Haemorrhagic events\*\*\*
Haemorrhagic events occurred in 20.6% of the 540 patients, including Grade 3 events in 3.7% of patients and a Grade 4 or fatal (Grade 5) event each occurred in one patient (0.2%).
Serious adverse reactions of haemorrhage were reported for 3.9% of patients.
Seventeen patients (3.1%) required dose interruption Dose reduction or permanent dose discontinuation due to haemorrhage occurred in 0.4% and 0.2% of patients, respectively.
\*\*\*QT prolongation\*\*\*
QT prolongation occurred in 5.2% of 540 patients with NSCLC or other solid tumours. In 2 patients (0.4%) the event was assessed as serious. The majority of patients experienced non-severe events – i.e. Grade 1, in 21 (3.9%) and Grade 2, in 5 patients (0.9%). Two patients (0.4%) experienced Grade 3 events of Electrocardiogram QT prolonged, which both resolved. There was no life-threatening or fatal QT prolongation. Three patients (0.6%) had an event that remained unresolved by time of data cut-off. Dose reductions or interruptions were required by two Electrocardiogram QT prolonged patients, each. No QT prolongation event led to permanent discontinuation of pralsetinib.
\*\*\*Infections\*\*\*
Infections were commonly experienced by 66.1% of 540 patients during the median treatment time of 15.9 months. Most frequently (>10%), pneumonia and urinary tract infection were reported (22.4% and 14.8%, respectively). The majority of infections were mild (Grade 1 or 2) and resolved; severe infection (Grade ≥3) occurred in 30.4% patients (with fatal events reported for 4.1%).
Infections reported as serious occurred for 18.5% of patients. The most common (>2%) serious infection was pneumonia (15.6%), followed by urinary tract infection (3.7%) and sepsis (3.7%). The majority of patients experiencing sepsis had concurrent pneumonia or urinary tract infection reported.
Dose interruption due to infection occurred in 12.8% of patients (mainly due to pneumonia [10.9%] and urinary tract infection [2.6%]). Dose was reduced due to infections in 3.7% of patients (mainly due to pneumonia [3.5%]). Permanent treatment discontinuation was required by 2.6% of patients due to infections (mainly due to pneumonia [2.6%]).
\*\*\*Elderly\*\*\*
In ARROW (N=540), 30.9% of patients were 65 years of age and older. Compared with younger patients (<65), more patients of ≥65 years old reported adverse reactions that led to permanent dose discontinuation (29.3% versus 18.8%). Of the commonly reported events with higher incidence in elderly patients (≥65), hypertension has the greatest difference in comparison with patients <65 years of age. However, hypertension is also expected to occur more frequently in the elderly population. Older patients reported more Grade 3 or higher adverse reactions compared to younger patients (89.8% versus 78.3%).
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
\*\*Symptoms\*\*
No cases of overdose have been reported in clinical trials with pralsetinib. The maximum dose of pralsetinib studied clinically is 600 mg orally once daily. Adverse reactions observed at this dose were consistent with the safety profile at 400 mg once daily (see section 4.8).
\*\*Management\*\*
There is no known antidote for Gavreto overdose. In the event of suspected overdose, Gavreto should be interrupted and supportive care instituted. Based on the large volume of distribution of pralsetinib and extensive protein binding, dialysis is unlikely to result in significant removal of pralsetinib.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitors, ATC code: L01EX23.
\*\*Mechanism of action\*\*
Pralsetinib is a potent protein kinase inhibitor that selectively targets oncogenic RET fusions (KIF5B-RET and CCDC6-RET). In NSCLC, RET fusions are one of the main oncogenic drivers. \*In vitro\*, pralsetinib inhibited several oncogenic RET fusions more potently than off-target kinases at clinically relevant concentrations (e.g. 81-fold selectivity over VEGFR2). Pralsetinib exhibited anti-tumour activity in cultured cells and animal tumour implantation models representing multiple tumour types harbouring oncogenic RET fusions (KIF5B-RET, CCDC6-RET).
\*\*Pharmacodynamic effects\*\*
\*\*\*Cardiac electrophysiology\*\*\*
The QT interval prolongation potential of pralsetinib was assessed in 34 patients with RET fusion-positive solid tumours administered at 400 mg once daily in a formal ECG sub-study.
In patients receiving pralsetinib in the ARROW study, QT prolongation was reported (see section 4.8). Therefore, dose interruption or modification may be required in patients treated with pralsetinib (see sections 4.2 and 4.4).
\*\*Clinical efficacy and safety\*\*
The efficacy of Gavreto was studied in patients with RET fusion-positive advanced NSCLC in Study BLU-667-1101 (ARROW), a multicenter, non-randomised, open-label, multi-cohort phase I/II clinical trial. The study enrolled, in separate cohorts, patients with RET fusion-positive advanced NSCLC who had progressed on platinum-based chemotherapy as well as patients that progressed on prior therapy other than platinum based therapy or were systemic treatment-naïve. The study was ongoing at the time of approval.
All NSCLC patients were required to have locally advanced or metastatic disease with measurable disease by Response Evaluable Criteria in Solid Tumours (RECIST) version 1.1. (v1.1) and have a RET fusion as determined by local testing (Next Generation Sequencing (NGS), fluorescence in situ hybridization (FISH), other). Patients with asymptomatic central nervous system (CNS) metastases, including patients with stable or decreasing steroid use within 2 weeks prior to study entry, were enrolled. The protocol excluded patients with a known primary driver alteration other than RET fusions, patients with a history of prolonged QT syndrome or Torsades de pointes or a familial history of prolonged QT syndrome, clinically symptomatic pneumonitis, and any prior or ongoing clinically significant medical condition that could affect patient's safety.
The primary efficacy outcome measure was overall response rate (ORR) according to RECIST v1.1 as evaluated by a Blinded Independent Central Review (BICR). Secondary efficacy outcomes included duration of response (DOR), progression free survival (PFS) and overall survival (OS).
\*\*\*Overall RET fusion-positive NSCLC population\*\*\*
The efficacy population consisted of 281 patients with RET fusion-positive advanced NSCLC who were treated at a starting dose of 400 mg orally once daily, including 116 who were treatment-naïve and 141 who previously received platinum-based chemotherapy. As of the last data cut-off date, the median follow-up was 24.1 months.
The demographic characteristics across the 281 patients were: 54.1% female, 46.3% White, 45.6% Asian, 3.6% Hispanic/Latino, and the median age was 60.0 years (range: 26 to 87) with 37.4% ≥65 years of age. The majority of patients had an ECOG performance status at baseline of 0 (29.5%) or 1 (68.0%), had metastatic disease (98.6%), had never smoked (62.6%) or were former smokers (33.1%) and had adenocarcinoma (96.8%). A history of brain metastases was seen in 34.5% of patients. Patients previously treated with platinum-based chemotherapy (N=141), received a median of 2 prior lines of therapy (range: 1-8). In addition to platinum-based chemotherapy, 40.4% received PD-1/PD-L1 inhibitors, 27.7% received multikinase inhibitors (MKIs) and 48.9% received prior radiation therapy. 15.5% of systemic treatment-naïve patients (N=116) received prior radiation therapy. RET fusions were detected in 75.8% of patients using NGS (36.7% tissue samples; 15.7% plasma samples, 23.5% unknown), 15.3% using FISH, 6.0% unknown, and 2.8% using other methods. The most common RET fusion partners were KIF5B (70.1%) and CCD6 (17.8%).
Efficacy results are summarised in Table 4. The median time to first response was 1.8 months for the overall population (range: 0.9-20.5 months), as well as for patients previously treated with platinum chemotherapy (range: 1.3-11.4 months) and treatment-naïve patients (range: 0.9-20.5 months).
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Table 4: Efficacy results for RET fusion-positive advanced NSCLC (ARROW) (efficacy population)\*\* | | | | |
| \*\*Efficacy parameter\*\* | \*\*Overall\*\* \*\*(N =281)\*\* | \*\*Previously treated with platinum chemotherapy\*\* \*\*(N=141)\*\* | \*\*Previously treated with non-platinum systemic treatment\*\* \*\*(N=24)\*\* | \*\*Treatment-naïve\*\* \*\*(N=116)\*\* |
| \*\*Overall response rate (ORR)\*\*a (95% CI) | 65.8% (60.0%, 71.4%) | 59.6% (51.0%, 67.7%) | 70.8% (48.9%, 87.4%) | 72.4% (63.3%, 80.3%) |
| Complete response, n (%) | 18 (6.4) | 10 (7.1) | 0 | 8 (6.9) |
| Partial response, n (%) | 167 (59.4) | 74 (52.5) | 17 (70.8) | 76 (65.5) |
| \*\*Duration of response (DOR)\*\* | \*\*N=185\*\* | \*\*N=84\*\* | \*\*N=17\*\* | \*\*N=84\*\* |
| DOR, median (95% CI) in months | 19.1 (14.5, 27.3) | 23.4 (14.8, 39.4) | 20.4 (9.3, NR) | 13.4 (9.4, 23.1) |
| Patients with DOR ≥ 6-monthsb, % | 79.5% | 81.0% | 94.1% | 75.0% |
NR= Not reached
a Confirmed overall response rate assessed by BICR
b Calculated using the proportion of responders with an observed duration of response at least 6 months or greater
No clinically relevant difference in efficacy was seen in patients with a KIF5B or CCDC6 fusion partner. BICR response rates were: ORR= 68.5% (95% CI: 61.5, 74.9) in 197 patients with a KIF5B fusion partner; and ORR= 72.0% (95% CI: 57.5, 83.8) in 50 patients with a CCDC6 fusion partner.
In the efficacy population, the CNS ORR by central assessment (per RECIST v1.1) was 53.3% (95% CI: 26.6, 78.7); 3 patients (20.0%) had a CR and 5 patients (33.3%) had a PR.
\*\*Elderly population\*\*
In ARROW (N=540), 30.9% of patients were 65 years of age and older. No overall differences in pharmacokinetic, safety or efficacy were observed in comparison with younger patients.
\*\*Paediatric population\*\*
The European Medicines Agency has waived the obligation to submit the results of studies with Gavreto in all subsets of the paediatric population in the treatment of lung cancer (small cell and non-small cell lung cancer) (see section 4.2 for information on paediatric use).
\*\*Conditional approval\*\*
This medicinal product has been authorised under a so-called 'conditional approval' scheme. This means that further evidence on this medicinal product is awaited.
The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.5.2 Pharmacokinetic properties
Pralsetinib Cmax and AUC in patients increased inconsistently over the dose range of 60 mg to 600 mg once daily (0.15 to 1.5 times the recommended dose); pharmacokinetics was linear in the dose range of 200 and 400 mg in healthy volunteers. Pralsetinib plasma concentrations reached steady state by 3 to 5 days.
At the recommended dose of 400 mg once daily under fasting conditions, the mean steady state Cmax of pralsetinib was 2840 ng/mL and the mean steady state area under the concentration-time curve (AUC0-24h) was 40100 h•ng/mL. The mean accumulation ratio was ~2-fold after repeated dosing.
\*\*Absorption\*\*
The median time to peak concentration (Tmax) ranged from 2.0 to 4.0 hours following single doses of pralsetinib 60 mg to 600 mg (0.15 to 1.5 times the approved recommended dose). The absolute bioavailability of pralsetinib has not been determined.
\*Effect of food\*
Following administration of a single dose of 200 mg Gavreto with a high-fat meal (approximately 800 to 1000 calories with 50 to 60% of calories from fat), the mean (90% CI) Cmax of pralsetinib was increased by 104% (65%, 153%), the mean (90% CI) AUC0-∞ was increased by 122% (96%, 152%), and the median Tmax was delayed from 4 to 8.5 hours, compared to the fasted state.
\*\*Distribution\*\*
The steady state mean apparent volume of distribution of pralsetinib is 255L. Plasma protein binding of pralsetinib is 97.1% and is independent of concentration. The blood-to-plasma ratio is 0.6 to 0.7.
\*\*Biotransformation\*\*
Pralsetinib is primarily metabolised by CYP3A4 and UGT1A4, and to a lesser extent by CYP2D6 and CYP1A2 \*in vitro\*.
Following a single oral dose of approximately 310 mg of radiolabelled pralsetinib to healthy subjects, pralsetinib metabolites from oxidation (M531, M453, M549b) and glucuronidation (M709) were detected in small to trace amounts (~ 5%).
\*\*Elimination\*\*
The mean plasma elimination half-life of pralsetinib was 13.4 hours following a single dose of 400 mg (the recommended dose) pralsetinib and 17.9 hours following multiple doses of 400 mg pralsetinib.
The steady state mean apparent oral clearance of pralsetinib (CL/F) is 9.9 L/h.
Following a single oral dose of radiolabelled pralsetinib to healthy subjects, 72.5% of the radioactive dose was recovered in faeces (66% as unchanged) and 6.1% in urine (4.8% as unchanged).
\*\*Interactions with CYP substrates\*\*
\*In vitro\* studies indicate that pralsetinib is a time-dependent inhibitor of CYP3A4/5 at clinically relevant concentrations. Pralsetinib may have the potential to inhibit or induce CYP2C8, CYP2C9, and CYP3A4/5 at clinically relevant concentrations.
\*\*Interactions with transport proteins\*\*
\*In vitro\* studies indicate that pralsetinib may have the potential to inhibit P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and MATE2-K at clinically relevant concentrations. Pralsetinib is a substrate of P-gp. (see section 4.5).
\*\*\*In vitro\* studies with drug transporters\*\*
\*In vitro\* studies indicate that pralsetinib may be a potential substrate of P-glycoprotein (P-gp) and BCRP at clinically relevant concentrations.
\*\*Special populations\*\*
Based on the population PK model, no clinically relevant differences in the pharmacokinetics of pralsetinib were observed based on age (19 to 87 years), sex, race (White, Black, or Asian), body weight (34.9 to 128 kg), mild hepatic impairment or mild to moderate renal impairment (CLCR 30 to 89 mL/min estimated by Cockcroft-Gault). Hence, no dose modifications are needed in the above-mentioned special populations. The effect of severe renal impairment (CLCR 15 to 29 mL/min), end-stage renal disease (CLCR < 15 mL/min) on the pharmacokinetics of pralsetinib is unknown (see section 4.2).
\*Hepatic Impairment\*
Following a single oral dose of 200 mg pralsetinib, peak pralsetinib exposure was similar in subjects with moderate hepatic impairment (as defined by Child-Pugh criteria) compared to subjects with normal hepatic function, with geometric mean ratios (GMR) (90% CI) of 98.6% (59.7, 163) for Cmax and 112% (65.4, 193) for AUC0-∞. In patients with severe hepatic impairment (as defined by Child-Pugh criteria), AUC0-∞ was also similar compared to subjects with normal hepatic function (85.8% [51.0, 144]). Cmax was slightly lower in subjects with severe hepatic impairment compared to subjects with normal hepatic function, with a Cmax GMR of 67.9% (35.3, 131). There was no clear relationship between Cmax or AUC and Child-Pugh total score or the components of the Child-Pugh score. Similar PK results were obtained when hepatic impairment subjects were classified by NCI-ODWG criteria.
Therefore, no dose adjustment is needed in patients with hepatic impairment.5.3 Preclinical safety data
\*\*Repeat-dose toxicity studies\*\*
In studies of up to 13 weeks duration in rats and cynomolgus monkeys, the primary findings at exposures similar to steady state human exposures (AUC) at 400 mg once daily in patients with advanced NSCLC included physeal dysplasia in the rat (2 times margin) and haematological effects (1 times margin) in both species. Additional adverse findings at higher exposures include degenerative changes in male and female reproductive organs (2 times margin) and increases in blood phosphorus with corresponding mineralization in soft tissues in rats (≥2 times margin), and myocardial haemorrhage in rats (4.4 times margin). Increased blood pressure was observed in rats after a single dose of 25 mg/kg (2 times). The No-Observed-Adverse-Effect-Level (NOAEL) of pralsetinib in the 13-week studies was 10 mg/kg/day in both species, corresponding to exposure (AUC) margins of 1 times relative to the human exposures. In a separate fertility and early embryonic development study in which male rats administered pralsetinib were mated with untreated female rats, intrauterine survival of the embryos (mean litter proportions of post-implantation loss and mean numbers and litter proportions of viable embryos) were unaffected by pralsetinib administration to males at the 20 mg/kg dose level (approximately 1.4 times the human exposure (AUC) at the clinical dose of 400 mg based on toxicokinetic data collected in this study). In addition, no pralsetinib-related effects on male reproductive performance (mating, fertility, and pregnancy indices) were observed in this study.
Regarding local exposure and toxicity, there was no evidence of gastrointestinal disturbance in either species up to the NOAEL dose of 10 mg/kg (0.9 times human margin). At higher doses in monkeys, gastrointestinal ulcerations and haemorrhage were observed.
\*\*Embryotoxicity / Teratogenicity\*\*
In an embryo-fetal development study, administration of pralsetinib to rats during the period of organogenesis was teratogenic and embryotoxic at exposures below the steady-state human clinical exposure (AUC) at 400 mg once daily dose. Malformations, including visceral (primarily kidney and ureter) and skeletal (vertebral, rib, costal cartilage, and vertebral central anomalies) were observed at approximately 0.2-fold of the human exposure. Postimplantation loss occurred at 0.5-fold of the human exposure, and increased to 100% incidence at 1.5-fold of human exposure.
\*\*Reproductive toxicity\*\*
In a dedicated fertility and early embryonic development study conducted in treated male rats mated to treated female rats pralsetinib did not have an effect on male or female mating performance or ability to become pregnant. However, consistent with the findings of the embryofetal development toxicology study there was post-implantation loss at doses as low as 5 mg/kg (approximately 0.3 times the human exposure (AUC) at the clinical dose of 400 mg based on toxicokinetic data from the 13-week rat toxicology study). At the 20 mg/kg dose level (approximately 2.5-3.6 times the human exposure) 82% of female rats had totally resorbed litters, with 92% post-implantation loss (early resorptions).
In a 13-week repeat-dose toxicology study, male rats exhibited microscopic evidence of tubular degeneration/atrophy in the testis with secondary cellular debris and reduced sperm in the lumen of the epididymis, which correlated with lower mean testis and epididymis weights and gross observations of soft and small testis. Female rats exhibited degeneration of the corpus luteum in the ovary. For both sexes, these effects were observed at pralsetinib doses ≥10 mg/kg/day, approximately 0.9 times the human exposure based on AUC at the clinical dose of 400 mg.
No findings were noted in the reproductive organs in a 13-week repeated-dose toxicology study in monkeys at dose levels up to 10 mg/kg/day (approximately 1 times the human exposure at the 400 mg once daily dose).
\*\*Genotoxicity and carcinogenicity\*\*
Pralsetinib was not mutagenic \*in vitro\* in the bacterial reverse mutation (Ames) assay and was negative in both \*in vitro\* human lymphocyte chromosome aberration assay and \*in vivo\* rat bone marrow micronucleus tests.
Carcinogenicity studies with pralsetinib have not been conducted.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
\*\*Capsule content\*\*
Hypromellose
Cellulose microcrystalline
Starch, pregelatinised
Sodium hydrogen carbonate
Citric acid
Magnesium stearate
\*\*Capsule shell\*\*
Brilliant blue FCF (E133)
Hypromellose
Titanium dioxide (E171)
\*\*Printing ink\*\*
Shellac
Propylene glycol (E1520)
Potassium hydroxide
Titanium dioxide (E171)6.2 Incompatibilities
Not applicable6.3 Shelf life
3 years.6.4 Special precautions for storage
This medicinal product does not require any special temperature storage conditions.
Store in the original package in order to protect from moisture.6.5 Nature and contents of container
High density polyethylene (HDPE) bottle with child-resistant closure (polypropylene) and foiled induction seal liner and desiccant sachet (silica gel)
Pack sizes: 60, 90 or 120 capsules.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Instruction Content
- ## Composition
Each hard capsule contains 100 mg of pralsetinib.
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Hard capsule.
Light blue, opaque hard capsule, size 0 (22 mm long x 7 mm wide) with “BLU-667” printed on the capsule shell body and “100 mg” on the capsule shell cap in white ink.
## Clinical Particulars
4.1 Therapeutic indications
Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.4.2 Posology and method of administration
Therapy should be initiated by a physician experienced in the administration of anticancer medicinal products.
Patient selection for treatment of RET fusion-positive advanced NSCLC should be based on a validated test method.
\*\*Posology\*\*
The recommended dose is 400 mg pralsetinib once daily on an empty stomach (see method of administration). Treatment should be continued until disease progression or unacceptable toxicity.
If vomiting occurs after taking a dose of pralsetinib, the patient should not take an additional dose but continue with the next scheduled dose.
\*Missed doses\*
If a dose of pralsetinib is missed, the patient should make up for the missed dose as soon as possible on the same day. The regular daily dose schedule for pralsetinib should be resumed the next day.
\*Dose modifications for adverse reactions\*
Interruption of treatment with or without dose reduction may be considered to manage adverse reactions based on severity and clinical presentation.
Patients may have their dose reduced by 100 mg decrements to a minimum dose of 100 mg once daily. Gavreto should be permanently discontinued in patients who are unable to tolerate 100 mg orally once daily.
Recommended dose modifications for adverse reactions are indicated in Table 1.
\*\*Table 1. Recommended dose modifications for Gavreto for adverse reactions\*\*
| | | |
| --- | --- | --- |
| \*\*Adverse reaction\*\* | \*\*Severitya\*\* | \*\*Dose modification\*\* |
| \*\*Pneumonitis/Interstitial lung disease (ILD)\*\* (see section 4.4) | Grade 1 or 2 | Interrupt treatment with Gavreto until resolution. Resume at a reduced dose. Permanently discontinue Gavreto for recurrent pneumonitis/ILD. |
| Grade 3 or 4 | Permanently discontinue for pneumonitis/ILD. |
| \*\*Hypertension\*\* | Grade 3 | Interrupt treatment with Gavreto for Grade 3 hypertension that persists despite optimal antihypertensive therapy. Resume at a reduced dose when hypertension is controlled. |
| Grade 4 | Permanently discontinue Gavreto. |
| \*\*Transaminase elevations\*\* | Grade 3 or 4 | Interrupt treatment with Gavreto and monitor aspartate aminotransferase (AST) and alanine aminotransferase (ALT) once weekly until resolution to Grade 1 or baseline. Resume at a reduced dose. If the transaminase elevation recurs at Grade 3 or higher, permanently discontinue treatment with Gavreto. |
| \*\*Haemorrhagic events\*\* | Grade 3 or 4 | Interrupt treatment with Gavreto until resolution to Grade 1. Resume at a reduced dose. Permanently discontinue Gavreto for life-threatening or recurrent severe haemorrhagic events. |
| \*\*QT prolongation\*\* | Grade 3 | Interrupt treatment with Gavreto for QTc intervals >500 ms until QTc interval returns to <470 ms. Resume at the same dose if risk factors that cause QT prolongation are identified and corrected. Resume treatment at a reduced dose if other risk factors that cause QT prolongation are not identified. |
| Grade 4 | Permanently discontinue Gavreto if the patient has life-threatening arrhythmia. |
| \*\*Other clinically significant adverse reactions\*\* (see section 4.8) | Grade 3 or 4 | Interrupt treatment with Gavreto until improvement to ≤Grade 2. Resume at a reduced dose. Permanently discontinue for recurrent Grade 4 adverse reactions. |
| a Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 | | |
\*Dose modification for use with strong cytochrome P-450 (CYP)3A4 inhibitors or combined P-glycoprotein (P-gp) and strong CYP3A4 inhibitors\*
Concomitant use of pralsetinib with known strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors should be avoided (see section 4.4 and section 4.5). If co-administration with a strong CYP3A4 inhibitor or combined P-gp and strong CYP3A4 inhibitor cannot be avoided, the current dose of pralsetinib should be reduced as recommended in Table 2. After the strong CYP3A4 inhibitor or combined P-gp and strong CYP3A4 inhibitor have been discontinued for 3 to 5 elimination half-lives, the pralsetinib dose that was taken prior to the use of the inhibitor should be resumed.
\*\*Table 2. Recommended dose modifications for Gavreto for co-administration with strong CYP3A4 inhibitors or combined P\*\*-\*\*gp and strong CYP3A4 inhibitors\*\*
| | |
| --- | --- |
| \*\*Current Gavreto dose\*\* | \*\*Recommended Gavreto dose\*\* |
| 400 mg orally once daily | 200 mg orally once daily |
| 300 mg orally once daily | 200 mg orally once daily |
| 200 mg orally once daily | 100 mg orally once daily |
\*Dose modification for use with strong CYP3A4 inducers\*
Concomitant use of pralsetinib with strong CYP3A4 inducers should be avoided (see section 4.4 and section 4.5).
If concomitant use with a strong CYP3A4 inducer cannot be avoided, the dose of pralsetinib should be increased to double the current pralsetinib dose starting on Day 7 of co-administration of pralsetinib with the strong CYP3A4 inducer. After the strong CYP3A4 inducer has been discontinued for at least 14 days, the pralsetinib dose that was taken prior to the use of the inducer should be resumed.
\*\*Special populations\*\*
\*Renal impairment\*
No dose adjustment is recommended for patients with mild or moderate renal impairment (creatinine clearance [CLCR] 30 to 89 mL/min estimated by Cockcroft-Gault). Pralsetinib has not been studied in patients with severe renal impairment (CLCR 15 to 29 mL/min) or end-stage renal disease (CLCR <15 mL/min). Since pralsetinib elimination via the kidney is negligible, no dose adjustment is required in patients with severe renal impairment or end-stage renal disease (see section 5.2).
\*Hepatic impairment\*
No dose adjustment is recommended for patients with mild (total bilirubin ≤ upper limit of normal [ULN] and aspartate aminotransferase [AST] > ULN or total bilirubin > 1 to 1.5 times ULN and any AST), moderate (total bilirubin > 1.5 to 3 times ULN and any AST) or severe hepatic impairment (total bilirubin > 3 times ULN and any AST) (see section 5.2).
\*Elderly\*
No dose adjustment is recommended for patients aged 65 years and above (see section 5.1).
\*Paediatric population\*
The safety and efficacy of pralsetinib in paediatric patients below 18 years of age with RET fusion-positive advanced NSCLC have not been established. No data are available.
\*\*Method of administration\*\*
Gavreto is for oral use. Patients should swallow the hard capsules whole with a glass of water, on an empty stomach. They should not eat for at least two hours before and at least one hour after taking pralsetinib (see section 5.2).4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.4.4 Special warnings and precautions for use
\*\*Pneumonitis/ILD\*\*
Severe, life-threatening or fatal cases of pneumonitis/ILD have been reported in patients who received pralsetinib in clinical trials (see section 4.8). Patients who present with clinically symptomatic pneumonitis or ILD were excluded from clinical trials.
Patients should be advised to contact their healthcare provider immediately to report new or worsening respiratory symptoms.
Patients who present with acute or worsening of respiratory symptoms indicative of pneumonitis/ILD (e.g., dyspnoea, cough, and fever) should be investigated to exclude other potential causes. If pneumonitis/ILD is considered to be related to pralsetinib, the dose of Gavreto should be interrupted, reduced or permanently discontinued based on severity of confirmed pneumonitis/ILD (see section 4.2).
\*\*Hypertension\*\*
Hypertension was observed in pralsetinib-treated patients in clinical trials (see section 4.8). Treatment-related hypertension was most commonly managed with anti-hypertensive medicinal products.
Treatment with Gavreto should not be initiated in patients with uncontrolled hypertension. Pre-existing hypertension should be adequately controlled before starting Gavreto treatment. Monitoring of blood pressure is recommended after 1 week, at least monthly thereafter and as clinically indicated. Anti-hypertensive therapy should be initiated or adjusted as appropriate. The dose should be interrupted, reduced, or permanently discontinued based on the severity of hypertension observed during treatment with Gavreto (see section 4.2).
\*\*Transaminase elevations\*\*
Severe cases of transaminase elevations have been reported in patients who received pralsetinib in clinical trials (see section 4.8).
ALT and AST should be monitored prior to initiating Gavreto, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Treatment with Gavreto should be interrupted, reduced or permanently discontinued based on severity of the transaminase elevation observed during treatment with Gavreto (see section 4.2).
\*\*Haemorrhagic events\*\*
Severe, including fatal, haemorrhagic events can occur with Gavreto. In patients with life-threatening or recurrent severe haemorrhage, Gavreto should be permanently discontinued (see section 4.2).
\*\*QT prolongation\*\*
Prolongation of the QT interval has been observed in patients who received Gavreto in clinical trials (see section 4.8). Therefore, before starting Gavreto treatment, patients should have a QTc interval ≤470 ms and serum electrolytes within normal range. Hypokalaemia, hypomagnesaemia, and hypocalcaemia should be corrected both prior and during Gavreto treatment. Electrocardiograms (ECGs) and serum electrolytes should be monitored at the end of the first week and of the first month of Gavreto treatment, then periodically, as clinically indicated, depending also on presence of other risk factors (e.g. intercurrent diarrhoea, vomiting, nausea, concomitant medications).
Pralsetinib should be used with caution in patients with medical history of cardiac arrhythmias or QT interval prolongation, as well as in patients on strong CYP 3A4 inhibitors or on medicinal products known to be associated with QT/QTc prolongation.
Gavreto may require interruption, dose modification, or discontinuation (see section 4.2).
\*\*Tuberculosis\*\*
Tuberculosis, mostly extrapulmonary, has been reported in patients receiving Gavreto. Before starting treatment, patients should be evaluated for active and inactive (“latent”) tuberculosis, as per local recommendations. In patients with active or latent tuberculosis, standard antimycobacterial therapy should be initiated before treatment with Gavreto is started.
\*\*Drug interactions\*\*
Co-administration of Gavreto with strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors should be avoided because they may increase the plasma concentration of pralsetinib (see sections 4.2 and 4.5).
Co-administration of Gavreto with strong CYP3A4 inducers should be avoided because they may decrease the plasma concentration of pralsetinib (see section 4.2 and section 4.5).
\*\*Fertility and pregnancy\*\*
During treatment with Gavreto and for at least 1 week after the final dose, male patients with female partners of childbearing potential must use effective contraception, including a barrier method (see section 4.6).
Women of childbearing potential should be advised to avoid becoming pregnant while receiving Gavreto. A highly effective non-hormonal method of contraception is required for female patients during treatment with pralsetinib, because pralsetinib can render hormonal contraceptives ineffective. If a hormonal method of contraception is unavoidable, then a condom must be used in combination with the hormonal method. Effective contraception must be continued for at least 2 weeks after the final dose (see section 4.6)\*.\*
\*\*Sodium content\*\*
This medicinal product contains less than 1 mmol sodium (23 mg) per hard capsule, that is to say essentially “sodium-free”.4.5 Interaction with other medicinal products and other forms of interaction
\*\*Pharmacokinetic interactions\*\*
\*In vitro\* data indicate that pralsetinib is primarily metabolised by CYP3A4 and transported by P-gp. Therefore, inducers and inhibitors of CYP3A4 and P-gp may alter the plasma concentrations of pralsetinib.
\*\*Active substances that may have an effect on pralsetinib\*\*
\*Strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors\*
Co-administration of pralsetinib with strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors can increase pralsetinib plasma concentrations, which may increase the incidence and severity of adverse reactions of pralsetinib. Co-administration of 200 mg pralsetinib once daily with itraconazole 200 mg once daily (a strong CYP3A4 and P-gp inhibitor) increased pralsetinib Cmax by 84% and AUC0-∞ by 251%, compared to pralsetinib administered alone.
Therefore, co-administration of pralsetinib with strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors (including, but not limited to, ritonavir, saquinavir, telithromycin, ketoconazole, itraconazole, voriconazole, posaconazole nefazodone, grapefruit or Seville oranges) should be avoided (see section 4.4). If co-administration with strong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors cannot be avoided, reduce the current dose of pralsetinib (section 4.2).
\*Strong CYP3A4 inducers\*
Co-administration of pralsetinib with strong CYP3A4 inducers can decrease pralsetinib plasma concentrations, which may decrease the efficacy of pralsetinib. Co-administration of 400 mg pralsetinib as a single dose with rifampin 600 mg once daily (a strong CYP3A4 inducer) decreased pralsetinib Cmax by 30% and AUC0-∞ by 68%. Based on a population PK analysis, CYP3A4 weak inducers decreased pralsetinib exposures, but were not clinically significant in patients with NSCLC.
Therefore, co-administration of pralsetinib with strong CYP3A4 inducers (including, but not limited to, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin and St. John's Wort [\*Hypericum perforatum\*]) should be avoided (see section 4.4). If co-administration cannot be avoided, increase the pralsetinib dose (see section 4.2).
\*Sensitive substrates of CYP3A4, CYP2C8, CYP2C9, P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1 and MATE2-K with narrow therapeutic index\*
Co-administration of pralsetinib can alter the exposure of sensitive substrates of CYP enzymes (CYP3A4, CYP2C9 and CYP2C8) and transporters (P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1 and MATE2-K)\*.\* Substrate drugs of these CYP enzymes and transporters with narrow therapeutic index (including, but not limited to cyclosporine, paclitaxel and warfarin) should be avoided.4.6 Fertility, pregnancy and lactation
\*\*Women of childbearing potential/Contraception in females and males\*\*
Women of childbearing potential should be informed that pralsetinib may cause foetal harm (see section 5.3).
The pregnancy status of women of childbearing potential should be verified prior to initiating Gavreto treatment.
Women of childbearing potential have to use highly effective non-hormonal contraception during treatment and for at least 2 weeks following the last dose of Gavreto (see section 4.4).
Males with female partners of childbearing potential must use effective contraception during, including a barrier method, treatment with Gavreto and for at least 1 week following the last dose of Gavreto.
Patients should be advised to contact their healthcare provider immediately if they become pregnant, or if pregnancy is suspected, while taking Gavreto.
\*\*Pregnancy\*\*
There are no data from the use of pralsetinib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).
Based on its mechanism of action and findings in animals, pralsetinib may cause foetal harm when administered to pregnant women.
Gavreto should not be used during pregnancy unless the clinical condition of the woman requires treatment with pralsetinib.
\*\*Breast-feeding\*\*
It is unknown whether pralsetinib or its metabolites are excreted in human milk.
A risk to the breast-fed child cannot be excluded.
Breast-feeding should be discontinued during treatment with Gavreto and for 1 week following the final dose.
\*\*Fertility\*\*
There is no clinical data on the effects of pralsetinib on fertility.
Based on non-clinical safety findings, fertility may be compromised during treatment with pralsetinib (see section 5.3). Men and women should seek advice on effective fertility preservation before treatment.4.7 Effects on ability to drive and use machines
Gavreto has minor influence on the ability to drive and use machines. Caution should be exercised when driving or operating machines as patients may experience fatigue while taking Gavreto (see section 4.8).4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
The most common adverse reactions were anaemia (53.0%), aspartate aminotransferase increased (49.1%), neutropenia (46.7%), musculoskeletal pain (44.4%), constipation (43.9%), fatigue (42.2%), alanine aminotransferase increased (37.0%), leukopenia (37.0%), and hypertension (35.0%).
The most common serious adverse reactions were pneumonia (15.6%), pneumonitis (5.7%) and anaemia (5.2%).
The most common severe adverse reactions were anaemia (22.4%), neutropenia (21.1%), hypertension (17.6%), pneumonia (15.4%), and lymphopenia (17.4%).
Based on the data from clinical trials, exposure-response relationships for any Grade 3 or 4 adverse reaction were observed at higher exposures, with a faster time to onset for adverse reactions with increasing pralsetinib exposure.
Dose reductions due to adverse reactions occurred in 46.7% of patients treated with Gavreto. The most common adverse reactions resulting in dose reductions were neutropenia (15.6%), anaemia (10.6%), lymphopenia (7.2%), pneumonitis (5.7%), blood creatine phosphokinase increased (5.2%), leukopenia (4.6%), hypertension (4.8%), and fatigue (4.1%).
Permanent discontinuation due to adverse reactions occurred in 10.6% of patients treated with Gavreto. The most common adverse reactions that led to permanent discontinuation of Gavreto were pneumonia and pneumonitis (2.6% and 2.2%, respectively).
\*\*Tabulated list of adverse reactions\*\*
The safety population includes a total of 540 patients, including 281 patients with advanced NCSLC, as well as patients with other solid tumours (including RET fusion thyroid cancer and RET mutation medullary thyroid cancer), who received pralsetinib at a starting dose of 400 mg, see section 5.1. No clinically relevant differences in the safety profile across indications have been observed.
Adverse reactions reported in patients treated with Gavreto in the ARROW trial are listed below (Table 3), according to the MedDRA System Organ Class and frequency.
Frequencies are defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), and not known (cannot be estimated from the available data).
Within each system organ class, adverse reactions are presented in order of decreasing frequency and severity.
| | | | |
| --- | --- | --- | --- |
| \*\*Table 3.\*\* \*\*Adverse reactions reported in all patients treated with 400 mg Gavreto in the ARROW trial (N=540)\*\* | | | |
| \*\*System organ class /\*\* Adverse reactions | \*\*Frequency category\*\* | \*\*All grades\*\* \*\*%\*\* | \*\*Grades 3-4\*\* \*\*%\*\* |
| \*\*Infections and infestations\*\* | | | |
| Pneumonia1 Urinary tract infection | Very common | 22.4 14.8 | 13.1 4.4 |
| \*\*Blood and lymphatic system disorders\*\* | | | |
| Anaemia2 Neutropenia3 Leukopenia4 Lymphopenia5 Thrombocytopenia6 | Very common | 53.0 46.7 37.0 26.9 19.6 | 22.421.1 8.9 17.4 4.8 |
| \*\*Metabolism and nutrition disorders\*\* | | | |
| Hypocalcaemia Hyperphosphataemia Hypoalbuminaemia Hypophosphataemia Hyponatraemia | Very common | 23.1 17.4 14.8 13.0 12.2 | 3.9 0.2 - 5.7 4.4 |
| \*\*Nervous system disorders\*\* | | | |
| Headache7 Taste disorder8 | Very common | 18.0 16.7 | 0.6 - |
| \*\*Vascular disorders\*\* | | | |
| Hypertension9 Haemorrhage10 | Very common | 35.0 20.6 | 17.6 3.9 |
| \*\*Respiratory, thoracic and mediastinal disorders\*\* | | | |
| Cough11 Dyspnoea Pneumonitis12 | Very common | 28.1 20.4 12.2 | 0.6 2.0 3.3 |
| \*\*Gastrointestinal disorders\*\* | | | |
| Constipation Diarrhoea Nausea Abdominal pain13 Dry mouth Vomiting | Very common | 43.9 33.1 19.6 17.8 16.5 14.8 | 0.6 3.1 0.2 1.5 - 1.1 |
| Stomatitis14 | Common | 6.9 | 1.3 |
| \*\*Hepatobiliary disorders\*\* | | | |
| Aspartate aminotransferase increased\\* Alanine aminotransferase increased\\* Hyperbilirubinaemia15 | Very common | 49.1 37.0 14.4 | 6.9 4.8 1.7 |
| \*\*Skin and subcutaneous tissue disorders\*\* | | | |
| Rash16 | Very common | 19.1 | - |
| \*\*Musculoskeletal and connective tissue disorders\*\* | | | |
| Musculoskeletal pain17 Blood creatine phosphokinase increased | Very common | 44.4 16.7 | 2.6 7.6 |
| \*\*General disorders and administration site conditions\*\* | | | |
| Fatigue18 Oedema19 Pyrexia | Very common | 42.2 31.5 27.8 | 4.1 0.2 1.5 |
| \*\*Cardiac disorders\*\* | | | |
| QT prolongation20 | Common | 5.2 | 0.4 |
| \*\*Renal and urinary disorders\*\* | | | |
| Blood creatinine increased | Very common | 25.4 | 0.6 |
| \*\*Investigations\*\* | | | |
| Blood alkaline phosphatase increased | Very common | 12.0 | 1.5 |
| 1 includes pneumonia, pneumocystis jirovecii pneumonia, pneumonia cytomegaloviral, atypical pneumonia, lung infection, pneumonia bacterial, pneumonia haemophilus, pneumonia influenzal, pneumonia streptococcal, pneumonia moraxella, pneumonia staphylococcal, pneumonia pseudomonal, atypical mycobacterial pneumonia, pneumonia legionella 2 includes anaemia, haematocrit decreased, red blood cell count decreased, haemoglobin decreased, aplastic anaemia 3 includes neutrophil count decreased, neutropenia 4 includes white blood cell count decreased, leukopenia 5 includes lymphopenia, lymphocyte count decreased 6 includes thrombocytopenia, platelet count decreased 7 includes headache, tension headache 8 includes ageusia, dysgeusia 9 includes hypertension, blood pressure increased 10 includes 39 preferred terms from the SMQ Haemorrhage (excl laboratory terms) narrow, with the exclusion of terms related to invasive drug administration, terms related to rupture, disseminated intravascular coagulopathy, terms related to traumatic haemorrhages, and haemorrhagic terms related to pregnancy, birth or neonatal 11 includes cough, productive cough 12 includes pneumonitis, interstitial lung disease 13 includes abdominal pain, abdominal pain upper 14 includes stomatitis, aphthous ulcer 15 includes blood bilirubin increased, hyperbilirubinaemia, bilirubin conjugated increased, blood bilirubin unconjugated increased 16 includes rash, rash maculo-papular, dermatitis acneiform, erythema, rash generalised, rash papular, rash pustular, rash macular, rash erythematous 17 includes musculoskeletal chest pain, myalgia, arthralgia, pain in extremity, neck pain, musculoskeletal pain, back pain, bone pain, spinal pain, musculoskeletal stiffness 18 includes asthenia, fatigue 19 includes oedema, swelling face, peripheral swelling, oedema peripheral, face oedema, periorbital oedema, eyelid oedema, generalised oedema, swelling, localised oedema 20 includes electrocardiogram QT prolonged, long QT syndrome \\* additionally, transaminases increased were reported in 3.7% (0.6% Grades 3-4) | | | |
\*\*Description of selected adverse reactions\*\*
\*\*\*Pneumonitis/ILD\*\*\*
Pneumonitis and ILD occurred in 12.2% of 540 patients with NSCLC or other solid tumours, enrolled in the ARROW Study who received Gavreto (see section 4.4). Among the patients who had pneumonitis/ILD, the median time to onset was 16.1 weeks.
Serious adverse reactions of pneumonitis/ILD were reported for 5.7% of patients, including Grade 3 events (2.8%), Grade 4 (0.6%) and one fatal (Grade 5) event (0.2%).
In clinical trials, the majority of the patients with Grade 1 or Grade 2 pneumonitis were able to continue treatment without recurrent pneumonitis/ILD following dose interruption and dose reduction. Dose interruption occurred in 8.9%, dose reduction in 5.7% and permanent dose discontinuation in 2.2% of patients due to ILD/pneumonitis. The median time to resolution was 4.3 weeks.
\*\*\*Hypertension\*\*\*
Hypertension (including blood pressure increased) occurred in 35.0% of 540 patients with NSCLC or other solid tumours, including Grade ≤2 events in 17.4% and Grade 3 in 17.6% of patients. No Grade 4 or Grade 5 events were reported. Among the patients who had hypertension, the median time to onset was 2.1 weeks.
Serious adverse reactions of hypertension were reported in 1.3% of all patients (all Grade 3 events).
Dose interruption occurred in 8.0% of patients, dose reduction in 4.8% and one patient (0.2%) required permanent dose discontinuation. The median time to resolution was 4.0 weeks.
\*\*\*Transaminase elevations\*\*\*
Increased AST occurred in 49.1% of 540 patients, including Grade 3 or 4 in 6.9% of patients. Increased ALT occurred in 37.0% of patients, including Grade 3 or 4 events in 4.8% of patients. The median time to first onset for increased AST was 2.1 weeks and increased ALT was 3.5 weeks.
Serious adverse reactions of increased AST and ALT were reported in 0.7% and 0.6% of patients, respectively.
Dose interruption due to increased AST or ALT occurred in 5.0% and 3.9% of patients, respectively and dose reduction in 2.0% and 1.5%, respectively. No patients required permanent dose discontinuation. The median time to resolution was 6.0 and 5.1 weeks for increased AST and ALT, respectively.
\*\*\*Haemorrhagic events\*\*\*
Haemorrhagic events occurred in 20.6% of the 540 patients, including Grade 3 events in 3.7% of patients and a Grade 4 or fatal (Grade 5) event each occurred in one patient (0.2%).
Serious adverse reactions of haemorrhage were reported for 3.9% of patients.
Seventeen patients (3.1%) required dose interruption Dose reduction or permanent dose discontinuation due to haemorrhage occurred in 0.4% and 0.2% of patients, respectively.
\*\*\*QT prolongation\*\*\*
QT prolongation occurred in 5.2% of 540 patients with NSCLC or other solid tumours. In 2 patients (0.4%) the event was assessed as serious. The majority of patients experienced non-severe events – i.e. Grade 1, in 21 (3.9%) and Grade 2, in 5 patients (0.9%). Two patients (0.4%) experienced Grade 3 events of Electrocardiogram QT prolonged, which both resolved. There was no life-threatening or fatal QT prolongation. Three patients (0.6%) had an event that remained unresolved by time of data cut-off. Dose reductions or interruptions were required by two Electrocardiogram QT prolonged patients, each. No QT prolongation event led to permanent discontinuation of pralsetinib.
\*\*\*Infections\*\*\*
Infections were commonly experienced by 66.1% of 540 patients during the median treatment time of 15.9 months. Most frequently (>10%), pneumonia and urinary tract infection were reported (22.4% and 14.8%, respectively). The majority of infections were mild (Grade 1 or 2) and resolved; severe infection (Grade ≥3) occurred in 30.4% patients (with fatal events reported for 4.1%).
Infections reported as serious occurred for 18.5% of patients. The most common (>2%) serious infection was pneumonia (15.6%), followed by urinary tract infection (3.7%) and sepsis (3.7%). The majority of patients experiencing sepsis had concurrent pneumonia or urinary tract infection reported.
Dose interruption due to infection occurred in 12.8% of patients (mainly due to pneumonia [10.9%] and urinary tract infection [2.6%]). Dose was reduced due to infections in 3.7% of patients (mainly due to pneumonia [3.5%]). Permanent treatment discontinuation was required by 2.6% of patients due to infections (mainly due to pneumonia [2.6%]).
\*\*\*Elderly\*\*\*
In ARROW (N=540), 30.9% of patients were 65 years of age and older. Compared with younger patients (<65), more patients of ≥65 years old reported adverse reactions that led to permanent dose discontinuation (29.3% versus 18.8%). Of the commonly reported events with higher incidence in elderly patients (≥65), hypertension has the greatest difference in comparison with patients <65 years of age. However, hypertension is also expected to occur more frequently in the elderly population. Older patients reported more Grade 3 or higher adverse reactions compared to younger patients (89.8% versus 78.3%).
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
\*\*Symptoms\*\*
No cases of overdose have been reported in clinical trials with pralsetinib. The maximum dose of pralsetinib studied clinically is 600 mg orally once daily. Adverse reactions observed at this dose were consistent with the safety profile at 400 mg once daily (see section 4.8).
\*\*Management\*\*
There is no known antidote for Gavreto overdose. In the event of suspected overdose, Gavreto should be interrupted and supportive care instituted. Based on the large volume of distribution of pralsetinib and extensive protein binding, dialysis is unlikely to result in significant removal of pralsetinib.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitors, ATC code: L01EX23.
\*\*Mechanism of action\*\*
Pralsetinib is a potent protein kinase inhibitor that selectively targets oncogenic RET fusions (KIF5B-RET and CCDC6-RET). In NSCLC, RET fusions are one of the main oncogenic drivers. \*In vitro\*, pralsetinib inhibited several oncogenic RET fusions more potently than off-target kinases at clinically relevant concentrations (e.g. 81-fold selectivity over VEGFR2). Pralsetinib exhibited anti-tumour activity in cultured cells and animal tumour implantation models representing multiple tumour types harbouring oncogenic RET fusions (KIF5B-RET, CCDC6-RET).
\*\*Pharmacodynamic effects\*\*
\*\*\*Cardiac electrophysiology\*\*\*
The QT interval prolongation potential of pralsetinib was assessed in 34 patients with RET fusion-positive solid tumours administered at 400 mg once daily in a formal ECG sub-study.
In patients receiving pralsetinib in the ARROW study, QT prolongation was reported (see section 4.8). Therefore, dose interruption or modification may be required in patients treated with pralsetinib (see sections 4.2 and 4.4).
\*\*Clinical efficacy and safety\*\*
The efficacy of Gavreto was studied in patients with RET fusion-positive advanced NSCLC in Study BLU-667-1101 (ARROW), a multicenter, non-randomised, open-label, multi-cohort phase I/II clinical trial. The study enrolled, in separate cohorts, patients with RET fusion-positive advanced NSCLC who had progressed on platinum-based chemotherapy as well as patients that progressed on prior therapy other than platinum based therapy or were systemic treatment-naïve. The study was ongoing at the time of approval.
All NSCLC patients were required to have locally advanced or metastatic disease with measurable disease by Response Evaluable Criteria in Solid Tumours (RECIST) version 1.1. (v1.1) and have a RET fusion as determined by local testing (Next Generation Sequencing (NGS), fluorescence in situ hybridization (FISH), other). Patients with asymptomatic central nervous system (CNS) metastases, including patients with stable or decreasing steroid use within 2 weeks prior to study entry, were enrolled. The protocol excluded patients with a known primary driver alteration other than RET fusions, patients with a history of prolonged QT syndrome or Torsades de pointes or a familial history of prolonged QT syndrome, clinically symptomatic pneumonitis, and any prior or ongoing clinically significant medical condition that could affect patient's safety.
The primary efficacy outcome measure was overall response rate (ORR) according to RECIST v1.1 as evaluated by a Blinded Independent Central Review (BICR). Secondary efficacy outcomes included duration of response (DOR), progression free survival (PFS) and overall survival (OS).
\*\*\*Overall RET fusion-positive NSCLC population\*\*\*
The efficacy population consisted of 281 patients with RET fusion-positive advanced NSCLC who were treated at a starting dose of 400 mg orally once daily, including 116 who were treatment-naïve and 141 who previously received platinum-based chemotherapy. As of the last data cut-off date, the median follow-up was 24.1 months.
The demographic characteristics across the 281 patients were: 54.1% female, 46.3% White, 45.6% Asian, 3.6% Hispanic/Latino, and the median age was 60.0 years (range: 26 to 87) with 37.4% ≥65 years of age. The majority of patients had an ECOG performance status at baseline of 0 (29.5%) or 1 (68.0%), had metastatic disease (98.6%), had never smoked (62.6%) or were former smokers (33.1%) and had adenocarcinoma (96.8%). A history of brain metastases was seen in 34.5% of patients. Patients previously treated with platinum-based chemotherapy (N=141), received a median of 2 prior lines of therapy (range: 1-8). In addition to platinum-based chemotherapy, 40.4% received PD-1/PD-L1 inhibitors, 27.7% received multikinase inhibitors (MKIs) and 48.9% received prior radiation therapy. 15.5% of systemic treatment-naïve patients (N=116) received prior radiation therapy. RET fusions were detected in 75.8% of patients using NGS (36.7% tissue samples; 15.7% plasma samples, 23.5% unknown), 15.3% using FISH, 6.0% unknown, and 2.8% using other methods. The most common RET fusion partners were KIF5B (70.1%) and CCD6 (17.8%).
Efficacy results are summarised in Table 4. The median time to first response was 1.8 months for the overall population (range: 0.9-20.5 months), as well as for patients previously treated with platinum chemotherapy (range: 1.3-11.4 months) and treatment-naïve patients (range: 0.9-20.5 months).
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Table 4: Efficacy results for RET fusion-positive advanced NSCLC (ARROW) (efficacy population)\*\* | | | | |
| \*\*Efficacy parameter\*\* | \*\*Overall\*\* \*\*(N =281)\*\* | \*\*Previously treated with platinum chemotherapy\*\* \*\*(N=141)\*\* | \*\*Previously treated with non-platinum systemic treatment\*\* \*\*(N=24)\*\* | \*\*Treatment-naïve\*\* \*\*(N=116)\*\* |
| \*\*Overall response rate (ORR)\*\*a (95% CI) | 65.8% (60.0%, 71.4%) | 59.6% (51.0%, 67.7%) | 70.8% (48.9%, 87.4%) | 72.4% (63.3%, 80.3%) |
| Complete response, n (%) | 18 (6.4) | 10 (7.1) | 0 | 8 (6.9) |
| Partial response, n (%) | 167 (59.4) | 74 (52.5) | 17 (70.8) | 76 (65.5) |
| \*\*Duration of response (DOR)\*\* | \*\*N=185\*\* | \*\*N=84\*\* | \*\*N=17\*\* | \*\*N=84\*\* |
| DOR, median (95% CI) in months | 19.1 (14.5, 27.3) | 23.4 (14.8, 39.4) | 20.4 (9.3, NR) | 13.4 (9.4, 23.1) |
| Patients with DOR ≥ 6-monthsb, % | 79.5% | 81.0% | 94.1% | 75.0% |
NR= Not reached
a Confirmed overall response rate assessed by BICR
b Calculated using the proportion of responders with an observed duration of response at least 6 months or greater
No clinically relevant difference in efficacy was seen in patients with a KIF5B or CCDC6 fusion partner. BICR response rates were: ORR= 68.5% (95% CI: 61.5, 74.9) in 197 patients with a KIF5B fusion partner; and ORR= 72.0% (95% CI: 57.5, 83.8) in 50 patients with a CCDC6 fusion partner.
In the efficacy population, the CNS ORR by central assessment (per RECIST v1.1) was 53.3% (95% CI: 26.6, 78.7); 3 patients (20.0%) had a CR and 5 patients (33.3%) had a PR.
\*\*Elderly population\*\*
In ARROW (N=540), 30.9% of patients were 65 years of age and older. No overall differences in pharmacokinetic, safety or efficacy were observed in comparison with younger patients.
\*\*Paediatric population\*\*
The European Medicines Agency has waived the obligation to submit the results of studies with Gavreto in all subsets of the paediatric population in the treatment of lung cancer (small cell and non-small cell lung cancer) (see section 4.2 for information on paediatric use).
\*\*Conditional approval\*\*
This medicinal product has been authorised under a so-called 'conditional approval' scheme. This means that further evidence on this medicinal product is awaited.
The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.5.2 Pharmacokinetic properties
Pralsetinib Cmax and AUC in patients increased inconsistently over the dose range of 60 mg to 600 mg once daily (0.15 to 1.5 times the recommended dose); pharmacokinetics was linear in the dose range of 200 and 400 mg in healthy volunteers. Pralsetinib plasma concentrations reached steady state by 3 to 5 days.
At the recommended dose of 400 mg once daily under fasting conditions, the mean steady state Cmax of pralsetinib was 2840 ng/mL and the mean steady state area under the concentration-time curve (AUC0-24h) was 40100 h•ng/mL. The mean accumulation ratio was ~2-fold after repeated dosing.
\*\*Absorption\*\*
The median time to peak concentration (Tmax) ranged from 2.0 to 4.0 hours following single doses of pralsetinib 60 mg to 600 mg (0.15 to 1.5 times the approved recommended dose). The absolute bioavailability of pralsetinib has not been determined.
\*Effect of food\*
Following administration of a single dose of 200 mg Gavreto with a high-fat meal (approximately 800 to 1000 calories with 50 to 60% of calories from fat), the mean (90% CI) Cmax of pralsetinib was increased by 104% (65%, 153%), the mean (90% CI) AUC0-∞ was increased by 122% (96%, 152%), and the median Tmax was delayed from 4 to 8.5 hours, compared to the fasted state.
\*\*Distribution\*\*
The steady state mean apparent volume of distribution of pralsetinib is 255L. Plasma protein binding of pralsetinib is 97.1% and is independent of concentration. The blood-to-plasma ratio is 0.6 to 0.7.
\*\*Biotransformation\*\*
Pralsetinib is primarily metabolised by CYP3A4 and UGT1A4, and to a lesser extent by CYP2D6 and CYP1A2 \*in vitro\*.
Following a single oral dose of approximately 310 mg of radiolabelled pralsetinib to healthy subjects, pralsetinib metabolites from oxidation (M531, M453, M549b) and glucuronidation (M709) were detected in small to trace amounts (~ 5%).
\*\*Elimination\*\*
The mean plasma elimination half-life of pralsetinib was 13.4 hours following a single dose of 400 mg (the recommended dose) pralsetinib and 17.9 hours following multiple doses of 400 mg pralsetinib.
The steady state mean apparent oral clearance of pralsetinib (CL/F) is 9.9 L/h.
Following a single oral dose of radiolabelled pralsetinib to healthy subjects, 72.5% of the radioactive dose was recovered in faeces (66% as unchanged) and 6.1% in urine (4.8% as unchanged).
\*\*Interactions with CYP substrates\*\*
\*In vitro\* studies indicate that pralsetinib is a time-dependent inhibitor of CYP3A4/5 at clinically relevant concentrations. Pralsetinib may have the potential to inhibit or induce CYP2C8, CYP2C9, and CYP3A4/5 at clinically relevant concentrations.
\*\*Interactions with transport proteins\*\*
\*In vitro\* studies indicate that pralsetinib may have the potential to inhibit P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and MATE2-K at clinically relevant concentrations. Pralsetinib is a substrate of P-gp. (see section 4.5).
\*\*\*In vitro\* studies with drug transporters\*\*
\*In vitro\* studies indicate that pralsetinib may be a potential substrate of P-glycoprotein (P-gp) and BCRP at clinically relevant concentrations.
\*\*Special populations\*\*
Based on the population PK model, no clinically relevant differences in the pharmacokinetics of pralsetinib were observed based on age (19 to 87 years), sex, race (White, Black, or Asian), body weight (34.9 to 128 kg), mild hepatic impairment or mild to moderate renal impairment (CLCR 30 to 89 mL/min estimated by Cockcroft-Gault). Hence, no dose modifications are needed in the above-mentioned special populations. The effect of severe renal impairment (CLCR 15 to 29 mL/min), end-stage renal disease (CLCR < 15 mL/min) on the pharmacokinetics of pralsetinib is unknown (see section 4.2).
\*Hepatic Impairment\*
Following a single oral dose of 200 mg pralsetinib, peak pralsetinib exposure was similar in subjects with moderate hepatic impairment (as defined by Child-Pugh criteria) compared to subjects with normal hepatic function, with geometric mean ratios (GMR) (90% CI) of 98.6% (59.7, 163) for Cmax and 112% (65.4, 193) for AUC0-∞. In patients with severe hepatic impairment (as defined by Child-Pugh criteria), AUC0-∞ was also similar compared to subjects with normal hepatic function (85.8% [51.0, 144]). Cmax was slightly lower in subjects with severe hepatic impairment compared to subjects with normal hepatic function, with a Cmax GMR of 67.9% (35.3, 131). There was no clear relationship between Cmax or AUC and Child-Pugh total score or the components of the Child-Pugh score. Similar PK results were obtained when hepatic impairment subjects were classified by NCI-ODWG criteria.
Therefore, no dose adjustment is needed in patients with hepatic impairment.5.3 Preclinical safety data
\*\*Repeat-dose toxicity studies\*\*
In studies of up to 13 weeks duration in rats and cynomolgus monkeys, the primary findings at exposures similar to steady state human exposures (AUC) at 400 mg once daily in patients with advanced NSCLC included physeal dysplasia in the rat (2 times margin) and haematological effects (1 times margin) in both species. Additional adverse findings at higher exposures include degenerative changes in male and female reproductive organs (2 times margin) and increases in blood phosphorus with corresponding mineralization in soft tissues in rats (≥2 times margin), and myocardial haemorrhage in rats (4.4 times margin). Increased blood pressure was observed in rats after a single dose of 25 mg/kg (2 times). The No-Observed-Adverse-Effect-Level (NOAEL) of pralsetinib in the 13-week studies was 10 mg/kg/day in both species, corresponding to exposure (AUC) margins of 1 times relative to the human exposures. In a separate fertility and early embryonic development study in which male rats administered pralsetinib were mated with untreated female rats, intrauterine survival of the embryos (mean litter proportions of post-implantation loss and mean numbers and litter proportions of viable embryos) were unaffected by pralsetinib administration to males at the 20 mg/kg dose level (approximately 1.4 times the human exposure (AUC) at the clinical dose of 400 mg based on toxicokinetic data collected in this study). In addition, no pralsetinib-related effects on male reproductive performance (mating, fertility, and pregnancy indices) were observed in this study.
Regarding local exposure and toxicity, there was no evidence of gastrointestinal disturbance in either species up to the NOAEL dose of 10 mg/kg (0.9 times human margin). At higher doses in monkeys, gastrointestinal ulcerations and haemorrhage were observed.
\*\*Embryotoxicity / Teratogenicity\*\*
In an embryo-fetal development study, administration of pralsetinib to rats during the period of organogenesis was teratogenic and embryotoxic at exposures below the steady-state human clinical exposure (AUC) at 400 mg once daily dose. Malformations, including visceral (primarily kidney and ureter) and skeletal (vertebral, rib, costal cartilage, and vertebral central anomalies) were observed at approximately 0.2-fold of the human exposure. Postimplantation loss occurred at 0.5-fold of the human exposure, and increased to 100% incidence at 1.5-fold of human exposure.
\*\*Reproductive toxicity\*\*
In a dedicated fertility and early embryonic development study conducted in treated male rats mated to treated female rats pralsetinib did not have an effect on male or female mating performance or ability to become pregnant. However, consistent with the findings of the embryofetal development toxicology study there was post-implantation loss at doses as low as 5 mg/kg (approximately 0.3 times the human exposure (AUC) at the clinical dose of 400 mg based on toxicokinetic data from the 13-week rat toxicology study). At the 20 mg/kg dose level (approximately 2.5-3.6 times the human exposure) 82% of female rats had totally resorbed litters, with 92% post-implantation loss (early resorptions).
In a 13-week repeat-dose toxicology study, male rats exhibited microscopic evidence of tubular degeneration/atrophy in the testis with secondary cellular debris and reduced sperm in the lumen of the epididymis, which correlated with lower mean testis and epididymis weights and gross observations of soft and small testis. Female rats exhibited degeneration of the corpus luteum in the ovary. For both sexes, these effects were observed at pralsetinib doses ≥10 mg/kg/day, approximately 0.9 times the human exposure based on AUC at the clinical dose of 400 mg.
No findings were noted in the reproductive organs in a 13-week repeated-dose toxicology study in monkeys at dose levels up to 10 mg/kg/day (approximately 1 times the human exposure at the 400 mg once daily dose).
\*\*Genotoxicity and carcinogenicity\*\*
Pralsetinib was not mutagenic \*in vitro\* in the bacterial reverse mutation (Ames) assay and was negative in both \*in vitro\* human lymphocyte chromosome aberration assay and \*in vivo\* rat bone marrow micronucleus tests.
Carcinogenicity studies with pralsetinib have not been conducted.
## Pharmaceutical Particulars
6.1 List of excipients
\*\*Capsule content\*\*
Hypromellose
Cellulose microcrystalline
Starch, pregelatinised
Sodium hydrogen carbonate
Citric acid
Magnesium stearate
\*\*Capsule shell\*\*
Brilliant blue FCF (E133)
Hypromellose
Titanium dioxide (E171)
\*\*Printing ink\*\*
Shellac
Propylene glycol (E1520)
Potassium hydroxide
Titanium dioxide (E171)6.2 Incompatibilities
Not applicable6.3 Shelf life
3 years.6.4 Special precautions for storage
This medicinal product does not require any special temperature storage conditions.
Store in the original package in order to protect from moisture.6.5 Nature and contents of container
High density polyethylene (HDPE) bottle with child-resistant closure (polypropylene) and foiled induction seal liner and desiccant sachet (silica gel)
Pack sizes: 60, 90 or 120 capsules.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Company Detail Path
- /organization/roche-products-limited
